Pmv Pharmaceuticals Inc
$ 1.09
2.83%
11 Jun - close price
- Market Cap 56,532,000 USD
- Current Price $ 1.09
- High / Low $ 1.09 / 1.03
- Stock P/E N/A
- Book Value 1.65
- EPS -1.48
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -0.63 %
- 52 Week High 1.88
- 52 Week Low 0.96
About
PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53 mutations in cancer. The company is headquartered in Cranbury, New Jersey.
Analyst Target Price
$4.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-06 | 2025-11-12 | 2025-08-07 | 2025-05-09 | 2025-03-03 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-09 |
| Reported EPS | -0.34 | -0.34 | -0.4 | -0.41 | -0.34 | -0.45 | -0.37 | -0.02 | -0.3 | -0.31 | -0.34 | -0.38 |
| Estimated EPS | -0.38 | -0.415 | -0.4 | -0.38 | -0.37 | -0.38 | -0.36 | -0.34 | -0.37 | -0.39 | -0.45 | -0.47 |
| Surprise | 0.04 | 0.075 | 0 | -0.03 | 0.03 | -0.07 | -0.01 | 0.32 | 0.07 | 0.08 | 0.11 | 0.09 |
| Surprise Percentage | 10.5263% | 18.0723% | 0% | -7.8947% | 8.1081% | -18.4211% | -2.7778% | 94.1176% | 18.9189% | 20.5128% | 24.4444% | 19.1489% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PMVP
2026-06-12 15:39:06
PMV Pharmaceuticals (PMVP) is experiencing a quiet trading session, bringing focus to its fundamentals, clinical pipeline, and cash position. As a clinical-stage oncology company, its valuation is currently based on its lead p53-targeted program, discovery platform, and balance sheet strength, with cash runway and operating losses being key metrics for investors given its pre-revenue status. The company's future hinges on successful clinical trials, regulatory approvals, and potential commercialization or licensing of its therapies, all of which carry significant risks.
2026-06-10 09:35:00
PMV Pharmaceuticals (PMVP) has dropped 26.1% in the past four weeks but may be poised for a trend reversal due to its oversold status, indicated by an RSI of 27.99. Additionally, Wall Street analysts have significantly raised their earnings estimates for the company, and PMVP holds a Zacks Rank #2 (Buy), suggesting a potential rebound. Investors might find entry opportunities as the stock's selling pressure could be exhausting itself.
2026-06-06 08:10:56
PMV Pharmaceuticals director Arnold J. Levine was granted 42,000 stock options at an exercise price of $1.1900 per share, as reported in a Form 4 SEC filing. These options are set to expire on June 4, 2036, and will vest on the earlier of June 4, 2027, or the company's next annual stockholders meeting. This transaction leaves him with a total of 42,000 options.
2026-06-06 06:10:40
PMV Pharmaceuticals director Kirsten Flowers was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. These options will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting. This insider transaction involves a grant/award of stock options rather than a purchase or sale of existing shares.
2026-06-05 20:40:11
PMV Pharmaceuticals director Charles M. Baum was granted 42,000 stock options with an exercise price of $1.19 per share, expiring on June 4, 2036. The options will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting. Following this transaction, Mr. Baum directly holds 42,000 stock options.
2026-06-05 20:40:11
PMV Pharmaceuticals director Carol Giltner Gallagher recently reported that she received a stock option grant for 42,000 shares and transferred options covering a total of 84,000 shares as bona fide gifts, primarily to The Gallagher Revocable Trust. These transactions were non-market transfers, not open-market buys or sells. The 42,000-share option has an exercise price of $1.19 per share, expires on June 4, 2036, and vests on the earlier of June 4, 2027, or the company’s next annual stockholders' meeting.
